logo
Ultragenyx Underscores Continued Commitment to Rare Disease Innovation with 2024 Impact Report

Ultragenyx Underscores Continued Commitment to Rare Disease Innovation with 2024 Impact Report

Yahoo14-05-2025
NOVATO, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) released its 2024 Impact Report today, which covers the company's approach to corporate responsibility. The report highlights efforts to transform the lives of individuals and families affected by rare diseases, empower its employees, and make a meaningful impact on the communities it operates within and serves.
'Since founding Ultragenyx 15 years ago, I've sought to build a next-generation rare disease company that has a meaningful and sustained impact on the entire rare disease community,' said Emil Kakkis, M.D., Ph.D., founder, president, and chief executive officer of Ultragenyx. 'Guided by the principle of doing the right thing, we have engineered our own dynamic approach to drug development while working on broader education and policy initiatives that meaningfully support diagnosis, drug development, regulatory pathways, and clinical care. The sustainability and social impact implications of our actions and decisions are consistently considered and reflected in our 2024 Impact Report.'
The company's approach to corporate responsibility is structured around six key pillars—Innovation, Patients, People, Communities, Planet, and Governance—aligned with its vision to lead the future of rare disease medicine and its mission to transform the lives of people with rare diseases. The 2024 Ultragenyx Impact Report features updates for all six pillars, as well as Sustainability Accounting Standards Board (SASB) and Global Reporting Initiative (GRI) indices. For the full report and more on Ultragenyx's Corporate Responsibility efforts, visit https://www.ultragenyx.com/ultra-committed/corporate-responsibility/.
Highlights from the company's 2024 report include:
Innovation:Ultragenyx is committed to developing and delivering transformative treatments where none exist.
Successfully transferred the manufacturing process of our DTX401 gene therapy to our Gene Therapy Manufacturing Facility (GTMF) in Bedford, Massachusetts
Advanced several key clinical programs to treat rare and ultra-rare diseases, including osteogenesis imperfecta (OI), Angelman syndrome, Sanfilippo syndrome type A (MPS IIIA), and glycogen storage disease type Ia (GSDIa)
Supported more than 80 clinical and non-clinical investigator-sponsored trials (ISTs) globally
Patients:Ultragenyx is committed to supporting the rare disease community through our efforts to develop novel therapies, share our science and expertise, achieve broad access to screening and treatment, and partner with policymakers for meaningful change.
Supported more than 650 patients in 50 countries in gaining access to Ultragenyx treatments through various global expanded access and patient assistance programs since 2013
Successfully advocated for the passage of newborn screening legislation in two more U.S. states
Hosted the ninth and tenth Rare Bootcamp to help patient families, foundations, and organizations seeking to develop novel treatments for rare diseases
People:Ultragenyx is committed to maintaining an inclusive, safe, and healthy environment. The company is also committed to fair and equitable compensation practices that are transparent and free from bias.
Launched the Executive Edge program to support the development of leadership skills at the vice president (VP) and senior VP levels
Maintained a high engagement score of 88% in our employee engagement survey
Communities:Ultragenyx is committed to supporting initiatives that provide meaningful impact for the rare disease community: public health and access to care, Science, Technology, Engineering, Arts, and Mathematics (STEAM) education, and local, at-risk communities.
Approved more than $3 million in charitable donations, independent medical education, and health-related grants across more than 20 countries
Hosted 2nd Annual Ultragenyx Global Days of Service, with employees volunteering in nearly 60 service projects
Planet:Ultragenyx is committed to implementing an environmental strategy that helps minimize its environmental footprint across its business.
Purchased 100% renewable electricity for our corporate headquarters campus in Novato, Calif.
Achieved My Green Lab Green certification at our Translational Sciences lab in Novato, Calif.
Governance:Ultragenyx is committed to strong corporate governance, ethics and integrity, compliance, data protection and security, and responsible procurement.
More than 90% of responders to the annual compliance culture survey stated that the annual compliance training is adequate for them to confidently execute their responsibilities
Maintained a formal Global Human Rights policy to hold ourselves and our vendors to its standards
Ultragenyx Receives External Recognition in 2024Ultragenyx's achievements in 2024 were consistently recognized through several prestigious awards.
In 2024, Ultragenyx was named one of the 100 Most Sustainable Companies by Barron's and one of the Top Places to Work in the USA for the second consecutive year, receiving six Cultural Excellence Awards from Top Workplaces. The company also received accolades from The Boston Globe and the San Francisco Chronicle. Additionally, the company was honored with the MassEcon Gold Award for Economic Impact in the Northeast region, celebrating its significant contributions to the Massachusetts economy, and was recognized as one of the Best Places for Working Parents in Massachusetts.
About UltragenyxUltragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultra-rare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease.
The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx's strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.
For more information on Ultragenyx, please visit the company's website at: www.ultragenyx.com.
Forward-Looking Statements and Use of Digital Media
This press release and the 2024 Ultragenyx Impact Report and other materials cross-referenced in this press release contain statements that are aspirational or reflective of our views about the company's future performance that constitute 'forward looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are generally identified through the inclusion of words such as 'aim,' 'anticipate,' 'aspire,' 'believe,' commit,' 'endeavor,' 'estimate,' 'expect,' 'goal,' 'intend,' 'may,' 'plan,' 'seek,' 'strive,' 'target,' 'will,' vision,' 'mission,' 'strategy,' 'commitment' and 'work,' or similar statements or variations of such terms and other similar expressions. The forward-looking statements in this document and the materials cross-referenced concern Ultragenyx's goals, progress or expectations with respect to corporate responsibility, sustainability, patients, products, product candidates, employees, environmental matters, policy and business risks and opportunities. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from those predicted in such statements. These statements are based on numerous assumptions that the company believes are reasonable but are open to a wide range of uncertainties and business risks. In addition, these statements may be based on standards for measuring progress that are still developing, controls and processes that continue to evolve, and assumptions that are subject to change in the future, and certifications, representations or data reviewed or provided by third parties Consequently, actual results may vary materially from what is contained in a forward-looking statement.
For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Ultragenyx in general, see Ultragenyx's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) on May 7, 2025, and its subsequent periodic reports filed with the SEC. Forward-looking statements are aspirational and are not guarantees or promises that goals or targets will be met. Ultragenyx undertakes no obligation to update any forward-looking or other statements, whether as a result of new information, future events, or otherwise, and notwithstanding any historical practice of doing so. Ultragenyx may determine to adjust any goals and targets or establish new ones to reflect changes in its business. The information included in, and any issues identified as material for purposes of, the 2024 Ultragenyx Impact Report is not an indication that they are considered material to Ultragenyx, its investors or other stakeholders, or required to be disclosed in the company's filings, in each case under SEC reporting or any other laws or requirements that may apply to the company. In the context of this report, the term 'material' is distinct from, and should not be confused with, such term as defined for SEC or other mandatory reporting purposes.
In addition to its SEC filings, press releases and public conference calls, Ultragenyx uses its investor relations website and social media outlets to publish important information about the company, including information that may be deemed material to investors, and to comply with its disclosure obligations under Regulation FD. Financial and other information about Ultragenyx is routinely posted and is accessible on Ultragenyx's Investor Relations website (https://ir.ultragenyx.com/) and LinkedIn website (https://www.linkedin.com/company/ultragenyx-pharmaceutical-inc-/).
Ultragenyx Contacts Investors Joshua Higa(415) 475-6370ir@ultragenyx.com
MediaJoey Fleurymedia@ultragenyx.com
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Alphabet Inc. (GOOGL): 'This Stock Should Be Up Much More,' Says Jim Cramer
Alphabet Inc. (GOOGL): 'This Stock Should Be Up Much More,' Says Jim Cramer

Yahoo

time25 minutes ago

  • Yahoo

Alphabet Inc. (GOOGL): 'This Stock Should Be Up Much More,' Says Jim Cramer

We recently published . Alphabet Inc. (NASDAQ:GOOGL) is one of the stocks Jim Cramer recently discussed. Cramer regularly discussed tech mega-cap Alphabet Inc. (NASDAQ:GOOGL) ahead of its earnings. The firm's shares have reversed course in July and are up by 1.9% year-to-date, primarily due to July's 9.9% gain. Before the report, Cramer was explicit in sharing that he regretted selling Alphabet Inc. (NASDAQ:GOOGL)'s stock. This time, he discussed the firm's businesses and shared that the stock should be higher after the earnings: [GOOGL]'[On earnings report] Yeah, look cloud was important. I think the big focus is frankly, uh, that paid clicks picked up 4%. I mean I was thinking paid clips might be down, I was worried that I felt that this was the beginning of the erosion and the cannibalization versus Gemini. That was completely wrong. YouTube up 200 million. Really, really fantastic. . . .Look the story here is this that the more chips that they get, better they're doing. They have so much demand I was quite surprised. 20 New Technology Trends for 2024 'This stock should be up much more than that. While we acknowledge the potential of GOOGL as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Tesla, Inc. (TSLA)'s 'A Cult Stock,' Says Jim Cramer
Tesla, Inc. (TSLA)'s 'A Cult Stock,' Says Jim Cramer

Yahoo

time25 minutes ago

  • Yahoo

Tesla, Inc. (TSLA)'s 'A Cult Stock,' Says Jim Cramer

We recently published . Tesla, Inc. (NASDAQ:TSLA) is one of the stocks Jim Cramer recently discussed. Tesla, Inc. (NASDAQ:TSLA) continues to face a horrible time on the stock market in 2025. The firm's shares have lost 16.7% year-to-date and fell by 8.2% after its latest earnings report, which missed analyst revenue and earnings estimates. The results were so bad that even Cramer, who believes that Tesla, Inc. (NASDAQ:TSLA)'s potential is in emerging technologies such as robotics, was forced to do somewhat of a turnaround: '[on revenue, vehicle sold, carbon credit all down] Okay, so you listen to the conference call, and they made it so that those don't matter. All that matters is self drive, autonomous. I'm not kidding. Robotaxi, uh, Austin, California. And then there's some lines, which says, where he's saying, and David you'll get a kick out of this I'm sure, he's talking about like in a few years like everyone's gonna be in this. The robotaxi's like going great. I mean, it's not doing anything. This was a call that was a fatuous call. David, I left out Turkey, number one. Netherlands and Austria. I knew that Austrian market, that was it. 'It's a cult stock. . . This was not the kind of conference call that I expected. I did not expect an immediate pivot to robots and the self driving and the robotaxi. While we acknowledge the potential of TSLA as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Honeywell International Inc. (HON): 'I Think You Buy' It, Says Jim Cramer
Honeywell International Inc. (HON): 'I Think You Buy' It, Says Jim Cramer

Yahoo

time25 minutes ago

  • Yahoo

Honeywell International Inc. (HON): 'I Think You Buy' It, Says Jim Cramer

We recently published . Honeywell International Inc. (NASDAQ:HON) is one of the stocks Jim Cramer recently discussed. Honeywell International Inc. (NASDAQ:HON) is one of the biggest industrial conglomerates in America. Its shares are flat year-to-date after a major 6% dip in July after the latest earnings results. The shares fell because despite the fact that the firm reported $10.4 billion in sales and $2.75 in EPS to beat analyst estimates of $10.1 billion and $2.66, investors were looking for a robust earnings performance to drive its guidance raise. Here's what Cramer said about Honeywell International Inc. (NASDAQ:HON) after the earnings: 'Okay, so Honeywell is splitting into three different companies. Some people feel that the cash flow is weaker, uh, I don't feel that this is nearly as and. . .I think you buy Honeywell. Only one division was weaker. This was automation. The stock tends to sell off when they report. And then it spends the next three weeks recovering. I think Honeywell is fine. Charitable trust owns it, it's a big win. It will continue to be a big win. This is a major overreaction to something that shouldn't be happening. Right now, shouldn't be happening. Down 15 you buy it. Copyright: zenstock / 123RF Stock Photo '[On guidance raise] Yes that's what matters. And people just always seize at whatever's most negative. They're breaking up into three companies. He's bringing out value. This is very short sighted. Vimal Kapoor doing a great job. Buy the stock. Overreaction to something that's not even negative for heaven's sake. Unbelievable how poorly the stock acts on the day it reports and then it spends the rest of the time, climbing. Buy it.' While we acknowledge the potential of HON as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store